This Aplisol market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed during the historical period can be attributed to increased awareness of public health threats, rising life expectancy, global immunization programs, the development of the BCG vaccine, and the growth of the aging population.
The projected growth in the forecast period is driven by a focus on preventive healthcare, better access to healthcare, a rise in research and development, the emergence of infectious diseases, and an emphasis on precision medicine. Key trends during the forecast period include the use of biosimilars, a focus on personalized medicine, the growth of remote monitoring, the development of patient-centric care models, and advancements in delivery systems.
The growing prevalence of tuberculosis (TB) is expected to drive the expansion of the aplisol market in the coming years. Tuberculosis is a contagious bacterial infection primarily affecting the lungs, caused by Mycobacterium tuberculosis, which can spread to other parts of the body if untreated. The rising prevalence of TB is influenced by factors such as the spread of drug-resistant strains, co-infection with HIV, socioeconomic conditions, increased global mobility, underreporting in healthcare systems, and delays in treatment due to stigma. Aplisol plays a crucial role in diagnosing TB through the Mantoux tuberculin skin test (TST), a primary method for detecting both latent and active TB infections. For example, according to a report from the UK Health Security Agency in February 2024, TB cases in the United Kingdom increased from 4,380 in 2022 to 4,850 in 2023, marking a 10.7% rise. Thus, the increasing prevalence of TB is driving the demand for aplisol.
The growth of the aplisol market is also supported by rising healthcare spending. Healthcare expenditure refers to the total financial resources allocated to medical services, infrastructure, pharmaceuticals, and healthcare-related activities. The increase in healthcare expenditure is driven by factors such as an aging population, a rise in chronic and lifestyle-related diseases, advancements in medical technology, and better access to healthcare services. Aplisol contributes to healthcare spending by covering the costs of testing, diagnosing, and following up with at-risk populations. For instance, the Office for National Statistics in the UK reported in May 2024 that healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a 0.9% rise in 2022. Moreover, long-term health and social care expenditure rose by 2.8% in real terms in 2022. As a result, growing healthcare expenditure is fueling the aplisol market.
In April 2024, Endo Inc., a US-based pharmaceutical company, acquired Endo International plc, a move aimed at diversifying its product portfolio and enhancing its pipeline with innovative drug candidates. Endo International plc specializes in branded pharmaceuticals, and this acquisition strengthens Endo's position in the market, potentially impacting the Aplisol market by broadening the availability of related healthcare products.
The key company operating in the aplisol market is JHP Pharmaceuticals LLC.
North America was the largest region in the aplisol market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in aplisol report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the aplisol market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Aplisol is a purified protein derivative (PPD) skin test used to detect tuberculosis (TB) infection. It is administered via intradermal injection to evaluate the body's immune response to antigens from Mycobacterium tuberculosis. A positive reaction suggests potential exposure to TB, though additional diagnostic tests are necessary to confirm an active infection.
The primary indications for aplisol are TB testing and assessment in BCG-vaccinated individuals. TB testing refers to diagnostic procedures to identify infection with the Mycobacterium tuberculosis bacteria, which causes TB. Aplisol is distributed through hospitals, clinics, and pharmacies, and it is used by adults, geriatric patients, and pediatric patients.
The aplisol market research report is one of a series of new reports that provides aplisol market statistics, including aplisol industry global market size, regional shares, competitors with a aplisol market share, detailed aplisol market segments, market trends and opportunities, and any further data you may need to thrive in the aplisol industry. This aplisol market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The aplisol market consists of sales of TST kits, Aplisol solutions, diagnostic reagents, and TST injection devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed during the historical period can be attributed to increased awareness of public health threats, rising life expectancy, global immunization programs, the development of the BCG vaccine, and the growth of the aging population.
The projected growth in the forecast period is driven by a focus on preventive healthcare, better access to healthcare, a rise in research and development, the emergence of infectious diseases, and an emphasis on precision medicine. Key trends during the forecast period include the use of biosimilars, a focus on personalized medicine, the growth of remote monitoring, the development of patient-centric care models, and advancements in delivery systems.
The growing prevalence of tuberculosis (TB) is expected to drive the expansion of the aplisol market in the coming years. Tuberculosis is a contagious bacterial infection primarily affecting the lungs, caused by Mycobacterium tuberculosis, which can spread to other parts of the body if untreated. The rising prevalence of TB is influenced by factors such as the spread of drug-resistant strains, co-infection with HIV, socioeconomic conditions, increased global mobility, underreporting in healthcare systems, and delays in treatment due to stigma. Aplisol plays a crucial role in diagnosing TB through the Mantoux tuberculin skin test (TST), a primary method for detecting both latent and active TB infections. For example, according to a report from the UK Health Security Agency in February 2024, TB cases in the United Kingdom increased from 4,380 in 2022 to 4,850 in 2023, marking a 10.7% rise. Thus, the increasing prevalence of TB is driving the demand for aplisol.
The growth of the aplisol market is also supported by rising healthcare spending. Healthcare expenditure refers to the total financial resources allocated to medical services, infrastructure, pharmaceuticals, and healthcare-related activities. The increase in healthcare expenditure is driven by factors such as an aging population, a rise in chronic and lifestyle-related diseases, advancements in medical technology, and better access to healthcare services. Aplisol contributes to healthcare spending by covering the costs of testing, diagnosing, and following up with at-risk populations. For instance, the Office for National Statistics in the UK reported in May 2024 that healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a 0.9% rise in 2022. Moreover, long-term health and social care expenditure rose by 2.8% in real terms in 2022. As a result, growing healthcare expenditure is fueling the aplisol market.
In April 2024, Endo Inc., a US-based pharmaceutical company, acquired Endo International plc, a move aimed at diversifying its product portfolio and enhancing its pipeline with innovative drug candidates. Endo International plc specializes in branded pharmaceuticals, and this acquisition strengthens Endo's position in the market, potentially impacting the Aplisol market by broadening the availability of related healthcare products.
The key company operating in the aplisol market is JHP Pharmaceuticals LLC.
North America was the largest region in the aplisol market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in aplisol report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the aplisol market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Aplisol is a purified protein derivative (PPD) skin test used to detect tuberculosis (TB) infection. It is administered via intradermal injection to evaluate the body's immune response to antigens from Mycobacterium tuberculosis. A positive reaction suggests potential exposure to TB, though additional diagnostic tests are necessary to confirm an active infection.
The primary indications for aplisol are TB testing and assessment in BCG-vaccinated individuals. TB testing refers to diagnostic procedures to identify infection with the Mycobacterium tuberculosis bacteria, which causes TB. Aplisol is distributed through hospitals, clinics, and pharmacies, and it is used by adults, geriatric patients, and pediatric patients.
The aplisol market research report is one of a series of new reports that provides aplisol market statistics, including aplisol industry global market size, regional shares, competitors with a aplisol market share, detailed aplisol market segments, market trends and opportunities, and any further data you may need to thrive in the aplisol industry. This aplisol market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The aplisol market consists of sales of TST kits, Aplisol solutions, diagnostic reagents, and TST injection devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Aplisol Market Characteristics4. Aplisol Market Trends and Strategies5. Aplisol Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Aplisol Pricing Analysis & Forecasts30. Global Aplisol Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Aplisol Market32. Recent Developments in the Aplisol Market
3. Aplisol Market Biologic Drug Characteristics
6. Global Aplisol Growth Analysis and Strategic Analysis Framework
8. Aplisol Market Segmentation
9. Global Aplisol Epidemiology of Clinical Indications
10. Aplisol Market Regional and Country Analysis
11. Asia-Pacific Aplisol Market
12. China Aplisol Market
13. India Aplisol Market
14. Japan Aplisol Market
15. Australia Aplisol Market
16. South Korea Aplisol Market
17. Western Europe Aplisol Market
18. UK Aplisol Market
19. Germany Aplisol Market
20. France Aplisol Market
21. Eastern Europe Aplisol Market
22. North America Aplisol Market
23. USA Aplisol Market
24. Canada Aplisol Market
25. South America Aplisol Market
26. Middle East Aplisol Market
27. Africa Aplisol Market
28. Aplisol Market Competitive Landscape and Company Profiles
29. Global Aplisol Market Pipeline Analysis
33. Aplisol Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Aplisol Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on aplisol market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for aplisol? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The aplisol market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Tuberculosis Testing; BCG Vaccinated Individuals2) by Distribution Channel: Hospital; Clinics; Pharmacies
3) by End Users: Adult; Geriatric; Pediatric
Key Companies Mentioned: JHP Pharmaceuticals LLC
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- JHP Pharmaceuticals LLC
